Bioglutide NA-931 Capsules

Shaanxi BLOOM Tech Co., Ltd. is one of the most experienced manufacturers and suppliers of bioglutide na-931 capsules in China. Welcome to wholesale bulk high quality bioglutide na-931 capsules for sale here from our factory. Good service and reasonable price are available.

Bioglutide NA-931 capsules are an innovative oral small molecule drug. As the world's first quadruple metabolite hormone receptor agonist, its core mechnism is to simultaneously activate the four major targets of IGF-1R, GLP-1R, GIPR, and GCGR, achieving metbolic balance reconstruction and body weight management through multi pathway synergistic effects. The drug is administered in the form of 100-150mg capsules once a day, breaking through the limitations of traditional weight loss drugs that rely on injections and providing patients with more convenient treatment options.

 

Our products

 

Bioglutide NA-931 COA

Certificate of Analysis
Compound name	Bioglutide NA-931
Grade	Pharmaceutical grade
CAS No.	N/A
Quantity	1g
Packaging standard	1g/Bag
Manufacturer	Shaanxi BLOOM TECH Co., Ltd
Lot No.	202501090028
MFG	Jan 9th 2025
EXP	Jan 8th 2028
Structure	N/A
Item	Enterprise standard	Analysis result
Appearance	White or almost white powder	Conformed
Water content	≤5.0%	0.34%
Loss on drying	≤1.0%	0.28%
Heavy Metals	Pb≤0.5ppm	N.D.
	As≤0.5ppm	N.D.
	Hg≤0.5ppm	N.D.
	Cd≤0.5ppm	N.D.
Purity (HPLC)	≥99.3%	99.90%
Single impurity	<0.8%	0.47%
Total microbial count	≤750cfu/g	97
E. Coli	≤2MPN/g	N.D.
Salmonella	N.D.	N.D.
Ethanol (by GC)	≤5000ppm	400ppm
Storage	Store in a sealed, dark, and dry place below 2-8°C

Each bioglutide NA-931 capsules contains a 10mg dose of the active ingredient. Kenny, a customer from the United States, has placed an order for 500 of these capsules. NA-931 is a peptide compound renowned for its distinctive biological properties. Within the field of biomedical research, it has attracted considerable interest due to its potential neuroprotective benefits.

Studies suggest it might play a role in fostering the growth, mending, and rejuvenation of nerve cells. It has exhibited promising outcomes in research models pertaining to neurological conditions like Alzheimer's disease and Parkinson's disease.

In the realm of health supplements, a segment of consumers holds the expectation that consuming NA931 capsules will contribute to preserving brain health. They also believe it could boost cognitive functions and memory, as well as slow down the brain's aging process.

 

Initial Cooperation and Product Advisory Session

Upon initially discovering Bloom Tech's range of peptide products, Kenny, enticed by curiosity and the prospect of market demand, decided to place an order. The delivery was swiftly made through FedEx's international express service, and Kenny received his shipment without any issues. He was highly pleased with both the caliber of the products and the level of service provided, laying a strong groundwork for future teamwork.

 

Following this positive experience, Kenny took the initiative to ask about additional products Bloom Tech offered, aside from their OEM capsule customization services. The sales representative, quick to sense this newfound interest, immediately shared a comprehensive link to the peptide product catalog, complete with a pricing guide.

The design of bioglutide NA-931 capsules is based on in-depth research on metbolic hormone receptors, and its quadruple target selection has a clear physiological basis:

1. GLP-1R: Classic metbolic regulatory target

 

GLP-1R belongs to the G proteide coupled receptor (GPCR) family and is widely distributed in pancreatic beta cells, gastrointestinal tract, central nervous system (hypothalamus), and cardiovascular system. Its natural ligand GLP-1 is secreted by intestinal L cells and has the following functions:

Blood glucose regulation: Promotes insulin secretion (glucose dependent) through the cAMP PKA pathway, inhibits glucagon secretion, and reduces hepatic glucose output.
Appetite suppression: activates thyrotropin releasing hormone (TRH) neurons in the hypothalamic arcuate nucleus, reducing hunger and increasing satiety.
Delayed gastric emptying: slows down the speed of food entering the small intestine from the stomach and prolongs the duration of satiety.

2. GIPR: a "synergistic enhancer" of insulin secretion

 

GIPR also belongs to the GPCR family and is mainly expressed in pancreatic beta cells and adipose tissue. The functions of its natural ligand GIP (glucose dependent insulin releasing polypeptide) include:

Post meal insulin secretion enhancement: synergizes with GLP-1 to significantly increase insulin secretion when blood glucose levels rise (such as after meals).
Fat metabolism regulation: promotes the uptake of glucose and triglyceride synthesis by adipocytes, possibly regulating energy balance through the central nervous system.
Bone protection: Recent studies have found that activation of GIPR can inhibit osteoclast activity and reduce bone resorption.

3. GCGR: The 'double-edged sword' of energy mobilization

 

GCGR is a receptor for glucagon, distributed in the liver, adipose tissue, and kidneys. Its activation effects include:

Fat breakdown: Promotes the release of free fatty acids (FFA) and glycerol from adipocytes through the cAMP PKA pathway.
Glycogenesis: Activation of phosphoenolpyruvate carboxykinase (PEPCK) and glucose-6-phosphatase (G6Pase) in the liver, converting non sugar substances such as lactate and glycerol into glucose.
Increased energy consumption: FFA can be used as fuel for sinews and heart utilization, while activating the thermogenic function of brown adipose tissue (BAT).
Challenge: Activating GCGR alone may lead to elevated blood sugar levels and sinews proteide breakdown, thus requiring coordination with other receptors to balance the effects.

 

IGF-1R: The 'Key Switch' for sinews Protection
IGF-1R belongs to the tyrosine kinase receptor family and is widely distributed in sinews, fat, liver, and bones. The functions of its natural ligand IGF-1 (insulin-like growth factor-1) include:

Muscle synthesis: Promotes sinews proteide synthesis through the PI3K AKT mTOR pathway and inhibits proteide degradation mediated by the ubiquitin proteasome system (UPS).
Improvement of insulin sensitivity: enhances glucose uptake by sinews and adipose tissue, reduces hepatic glucose output.
Anti apoptotic effect: protects cells from oxidative stress and inflammatory damage.

The target selection logic of product: By simultaneously activating GLP-1R (glucose lowering+food suppression), GIPR (enhanced insulin secretion), GCGR (promotes fat breakdown+energy expenditure), and IGF-1R (protects sinews+improves insulin sensitivity), it achieves a synergistic effect of "reducing fat without reducing sinews, lowering blood sugar without lowering blood sugar", overcoming the limitations of traditional single target drugs.

By simultaneously activating four metbolic hormone receptors, a multidimensional regulatory network is formed, and its mechnism is highly compatible with the physiological needs of exercise gain:

IGF-1R activation and sinews protection

 

IGF-1 (insulin-like growth factor-1) is a core factor in sinews growth and anti-aging. By activating IGF-1R, sinews proteide synthesis can be promoted, degradation can be inhibited, and sinews stem cell activity can be enhanced. This mechnism has been validated in the elderly population: similar drugs (such as MK-677) significantly improve sinews mass and function in the elderly by increasing IGF-1 levels. For athletes or fitness enthusiasts, reducing sinews micro injuries caused by training and accelerating repair may shorten the recovery period, thereby supporting higher intensity training loads.

GLP-1R and GIPR synergistically regulate fat metabolism

 

GLP-1R agonists (such as semaglutide) achieve weight loss by suppressing appetite, delaying gastric emptying, and promoting fat breakdown. GIPR further optimizes metabolism by enhancing insulin secretion and regulating adipose tissue function. The dual receptor activation of NA-931 can form a positive cycle of "fat breakdown energy supply": during exercise, fat breakdown accelerates to provide sustained energy to sinews, while reducing the breakdown energy supply of sinews proteides, thereby protecting lean body mass.

GCGR activation and energy mobilization

 

Activation of glucagon receptor (GCGR) can promote hepatic glycogen breakdown and fat breakdown, enhancing energy availability during exercise. Although traditional GCGR agonists may pose a risk of hyperglycemia, Bioglutide NA-931 capsules can balance blood glucose levels and avoid fluctuations in energy supply through its synergistic effect with GLP-1R/GIPR. This characteristic makes it a potential adjuvant drug for endurance sports such as marathons and triathlons, which can delay fatigue by optimizing energy substrate utilization.

Although its application in the field of motion gain is still in the speculative stage, the following research directions can provide scientific basis for its transformation:

Athlete specific clinical trials

 

A randomized controlled trial needs to be designed for athletes or fitness populations to evaluate the effects of NA-931 on sinews strength, endurance, explosive power, and other indicators. For example, the changes in sinews cross-sectional area during resistance training cycles can be compared to placebo, or the energy substrate utilization efficiency during aerobic exercise can be tested.

Dose and treatment optimization

 

The existing obesity treatment data suggests that the efficacy may be dose-dependent (12.7% weight loss at 12 weeks vs. 6.4% weight loss at 28 days). In the future, it is necessary to explore the optimal dosage regimen for exercise gain, such as whether low-dose long-term use can maintain the balance between sinews synthesis and fat breakdown, or whether high-dose short-term use is suitable for the pre competition weight loss period.

Combination therapy strategy

 

It can be used in combination with other sports nutrition supplements (such as creatine, β - hydroxy - β - methylbutyrate) or drugs (such as selective androgen receptor modulators) to enhance sinews synthesis or reduce sinews breakdown. For example, combining with creatine may enhance ATP synthesis efficiency and further optimize exercise performance.

Anti doping compliance assessment

 

Sports enhancing drugs need to be tested by the World Anti Doping Agency (WADA). As a novel multi-target agonist, NA-931 needs to be clarified whether it is a prohibited substance or whether structural modification can reduce the risk of doping.

Hot Tags: bioglutide na-931 capsules, suppliers, manufacturers, factory, wholesale, buy, price, bulk, for sale